Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Stem Cells (Dayton, Ohio)|February 12, 2016
β-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived SacsAtsushi Fujita, Naoya Uchida, Juan J Haro-Mora, et al.
Advances in Experimental Medicine and Biology|February 5, 2019
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and ChallengesSelami Demirci, Alexis Leonard, Juan J Haro-Mora, et al.
Stem Cells Translational Medicine|February 9, 2020
Biallelic correction of sickle cell disease-derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum-free iPS-sac/erythroid differentiationJuan J Haro-Mora, Naoya Uchida, Selami Demirci, et al.
Experimental Hematology|March 11, 2018
High-level embryonic globin production with efficient erythroid differentiation from a K562 erythroleukemia cell lineNaoya Uchida, Juan J Haro-Mora, Selami Demirci, et al.
Stem Cells (Dayton, Ohio)|October 15, 2016
Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells from Patients with Sickle Cell DiseaseNaoya Uchida, Juan J Haro-Mora, Atsushi Fujita, et al.
Molecular Therapy. Methods & Clinical Development|May 17, 2018
Serum-free Erythroid Differentiation for Efficient Genetic Modification and High-Level Adult Hemoglobin ProductionNaoya Uchida, Selami Demirci, Juan J Haro-Mora, et al.
Cytotherapy|September 26, 2018
Robust erythroid differentiation system for rhesus hematopoietic progenitor cells allowing preclinical screening of genetic treatment strategies for the hemoglobinopathiesSelami Demirci, Saurabh K Bhardwaj, Naoya Uchida, et al.
Calcified Tissue International|February 17, 2009
Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant statesBernardo Nuche-Berenguer, Paola Moreno, Pedro Esbrit, et al.
British Journal of Haematology|April 12, 2019
Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recoveryAlexis Leonard, Aylin Bonifacino, Venina M Dominical, et al.
Molecular Therapy. Methods & Clinical Development|January 1, 2020
Low-Dose Busulfan Reduces Human CD34+ Cell Doses Required for Engraftment in c-kit Mutant Immunodeficient MiceAlexis Leonard, Morgan Yapundich, Tina Nassehi, et al.
Pageof 3